- Lee, Jee-Yon;
- Cevallos, Stephanie A;
- Byndloss, Mariana X;
- Tiffany, Connor R;
- Olsan, Erin E;
- Butler, Brian P;
- Young, Briana M;
- Rogers, Andrew WL;
- Nguyen, Henry;
- Kim, Kyongchol;
- Choi, Sang-Woon;
- Bae, Eunsoo;
- Lee, Je Hee;
- Min, Ui-Gi;
- Lee, Duk-Chul;
- Bäumler, Andreas J
The clinical spectra of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) intersect to form a scantily defined overlap syndrome, termed pre-IBD. We show that increased Enterobacteriaceae and reduced Clostridia abundance distinguish the fecal microbiota of pre-IBD patients from IBS patients. A history of antibiotics in individuals consuming a high-fat diet was associated with the greatest risk for pre-IBD. Exposing mice to these risk factors resulted in conditions resembling pre-IBD and impaired mitochondrial bioenergetics in the colonic epithelium, which triggered dysbiosis. Restoring mitochondrial bioenergetics in the colonic epithelium with 5-amino salicylic acid, a PPAR-γ (peroxisome proliferator-activated receptor gamma) agonist that stimulates mitochondrial activity, ameliorated pre-IBD symptoms. As with patients, mice with pre-IBD exhibited notable expansions of Enterobacteriaceae that exacerbated low-grade mucosal inflammation, suggesting that remediating dysbiosis can alleviate inflammation. Thus, environmental risk factors cooperate to impair epithelial mitochondrial bioenergetics, thereby triggering microbiota disruptions that exacerbate inflammation and distinguish pre-IBD from IBS.